BioXcel Therapeutics Inc (BTAI)

NASDAQ
30.70
+0.09(+0.29%)
After Hours
30.71
+0.01(+0.03%)
- Real-time Data
  • Volume:
    777,653
  • Bid/Ask:
    30.43/32.00
  • Day's Range:
    30.41 - 32.00

BTAI Overview

Prev. Close
30.61
Day's Range
30.41-32
Revenue
-
Open
30.74
52 wk Range
23.07-67.74
EPS
-4.12
Volume
777,653
Market Cap
858.65M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
383,900
P/E Ratio
-
Beta
1.06
1-Year Change
-36.57%
Shares Outstanding
27,968,988
Next Earnings Date
Nov 18, 2021
What is your sentiment on BioXcel Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

BioXcel Therapeutics Inc News

BioXcel Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellBuyBuyBuy
Technical IndicatorsSellSellStrong BuyStrong BuyStrong Sell
SummaryStrong SellSellStrong BuyStrong BuyNeutral

BioXcel Therapeutics Inc Company Profile

BioXcel Therapeutics Inc Company Profile

Employees
50

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Read More
  • Will go up this week: BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call and Webcast https://www.bioxceltherapeutics.com/news-media/press-releases/detail/153/bioxcel-therapeutics-to-host-fourth-quarter-and-full-year
    0
    • Up 998% on a 52 week change
      0
      • Finally this is heading to where it should !
        0
        • up 300% in just over a year
          0
          • where could this go??
            0
        • B of A Securities Initiates Coverage On $BTAI with Buy Rating, PT to $45, while BMO Capital has it $65
          0
          • time to add more
            0
            • BioXcel has been outrageous!!
              1
              • At least $5.2 today
                2
                • Anyone have opinion on this share?
                  1
                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.